ATRX/DAXX in EUS-FNB Specimens of Pan-NETs

Launched by AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA · May 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a specific type of pancreatic tumor called pancreatic neuroendocrine tumors (pNETs), focusing on how certain genetic markers (DAXX and ATRX) could help doctors better understand the aggressiveness of these tumors. The researchers want to see if testing for these markers, along with the current method of grading tumors based on a cell growth indicator called the Ki67 index, can provide valuable information about the patient's condition. The study aims to improve the way doctors assess and treat non-functional pNETs, which are tumors that do not produce excess hormones.

To participate in this trial, you must be at least 18 years old, have a confirmed diagnosis of pNETs, and be able to give informed consent. Unfortunately, people with certain conditions, such as multiple pancreatic nodules or specific genetic syndromes, or those who are pregnant or breastfeeding, cannot participate. If you join the study, you will undergo testing that includes an endoscopic ultrasound and fine-needle biopsy (a procedure to collect tissue samples). The trial is currently recruiting participants, and your involvement could help advance our understanding and treatment of pancreatic neuroendocrine tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Cyto/histologic diagnosis of pNETs
• • Signed informed consent
• Exclusion Criteria:
• • Functional pNETs
• • Multiple pancreatic nodules
• • Diagnosis of MEN-1 or Von-Hippel Lindau
• • Mixed types (e.g., mixed neuroendocrine-acinar/adenocarcinoma) or neuroendocrine carcinomas
• • Predominantly cystic lesions (more than 50% of the volume).
• • Metastatic tumors at the time of diagnosis
• • Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma
• • Use of anticoagulants that cannot be discontinued
• • INR \>1.5 or platelet count \<50.000
• • Pregnancy or breastfeeding
• • Failure to sign the patient's or closest relative's informed consent